Experts from across the drug discovery ecosystem will explore the technologies, strategies, therapies and investment trends shaping early-stage drug discovery at the Drug Discovery Innovators & Investors (DDII) Digital Forum on 30 September. The Forum is free to attend. Register for the full event, or simply join one of the… Read More
ENA Respiratory has dosed the first participants in Part B of its Phase IIa community study of INNA-051, a virus-agnostic, dry powder nasal spray. INNA-051 is designed to prime the natural antiviral host defences in the nose where common respiratory viruses like rhinovirus, flu, RSV and coronaviruses… Read More
Chris Molloy, Chief Executive Officer of the UK BioIndustry Association (BIA), will explore the UK’s role in the changing global drug R&D landscape in his keynote address at the Drug Discovery Innovators & Investors (DDII) UK Conference on 4 November 2026 at etc.venues Monument, London, UK. Read More
The final patient has been treated in EMERALD, Resolution Therapeutics’ Phase I/II clinical trial evaluating its engineered Regenerative Macrophage Therapy (RMT), RTX001, in patients with end-stage liver disease (ESLD) and a history of decompensated liver cirrhosis. Liver transplantation remains the only disease-modifying treatment option for patients with… Read More
MaaT Pharma has received a negative trend vote from the Committee for Medicinal Products for Human Use (CHMP) for MaaT013 (Xervyteg) following re-examination for its conditional marketing authorisation application. The committee’s concerns relate primarily to the attribution of clinical benefit and safety in the absence of a… Read More
A new study has revealed how an mRNA-based influenza vaccine reshapes immune responses at the cellular and molecular levels. By tracking germinal-centre (GC) activity and individual secreted antibody clonotypes for up to six months, researchers uncovered how vaccination drives the evolution and diversification of immune responses. … Read More
AI start-up deepmirror has been awarded a Phase 2 Sovereign AI grant as part of Innovate UK’s support for British businesses building world-leading AI technologies. The grant will fund deepmirror’s data acquisition strategy in which it selects the experiments most likely to improve its molecular… Read More
Revvity has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specialising in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s… Read More
Ratio Therapeutics and RayzeBio have entered into a research collaboration and license agreement to advance a novel radiopharmaceutical programme focused on two undisclosed targets. Under the terms of the agreement, Ratio will receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments,… Read More
CONNECTA Therapeutics has closed a €3.1 million financing led by new investor Clave Capital through its Innvierte Science Tech Clave Innohealth, FCR fund. The funds will support CONNECTA in accelerating the Phase IIa clinical trial of CTH120 in adult males with Fragile X syndrome (FXS). … Read More
Teitur Trophics has announced successful results from its Phase I clinical trial of lead asset TT-P34 in healthy volunteers and patients with early-stage Parkinson’s disease (PD). The data show TT-P34 crosses the blood-brain barrier, leading to robust, dose-dependent exposure within the brain and central nervous system (CNS). Read More
Genomics drug discovery company OutSee has been awarded funding through Innovate UK’s Investor Partnership Grant, jointly provided by Innovate UK and Empirical Ventures. The grant will enable OutSee to conduct a pilot study for a prototype target validation sub-system, designed for initial triage of potential drug targets… Read More
Infex Therapeutics has presented new data from its Phase IIa study of RESP-X (INFEX702), a first-in-class anti-virulence monoclonal antibody, in non-cystic fibrosis bronchiectasis (NCFB) patients colonised with Pseudomonas aeruginosa (Pa). The results were presented at the European Respiratory Society (ERS) Congress 2026 in Barcelona, Spain. … Read More
G protein-coupled receptors (GPCRs) form one of the largest drug target families, with 516 approved drugs targeting GPCRs. They play a central role in cellular signalling pathways, including neurotransmission, immune response and metabolic regulation, making them key targets for therapeutic intervention. Currently approved drugs act on 121 GPCR… Read More
Teva Pharmaceutical has announced positive topline results from an ongoing Phase IIa study of TEV ‘408, an investigational anti-interleukin-15 monoclonal antibody, in adults with coeliac disease. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week… Read More
Ultragenyx Pharmaceutical has revealed that its Phase III Aspire study for apazunersen (GTX-102) in Angelman syndrome did not achieve its primary endpoint of change from Baseline in Bayley-4 cognitive raw score. The trial also failed to achieve the key secondary endpoint of net response in Multidomain Responder… Read More
